GlassScriptPhysician profile
Mark Fisher
NPI 1740608231
$1,991.13
in general payments reported to CMS, 2019-2025
13 companies · $758 in 2025
The $758 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $333 · 2021: $374 · 2022: $187 · 2023: $74.84 · 2024: $265 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $585 · Food and Beverage: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $585.00 |
| Food and Beverage | $512.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $585.00 | 2025 | |
| Mentor Worldwide LLC | $302.28 | 2023-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Medical Device Business Services, INC. | $274.99 | 2021 | |
| Stryker Corporation | $243.87 | 2020 | |
| Kls-Martin L.P. | $188.44 | 2020-2021 | |
| Access Pro Medical, LLC | $152.88 | 2022 | |
| Polynovo North America LLC | $61.43 | 2024 | Novosorb Btm |
| Abbvie INC. | $49.16 | 2023-2024 | |
| Musculoskeletal Transplant Foundation INC. | $43.17 | 2024 | |
| Motiva USA, LLC | $34.28 | 2025 | |
| Organogenesis INC. | $21.98 | 2024 | Cygnus Dual |
| Acelrx Pharmaceuticals, INC. | $19.90 | 2022 | |
| Kerecis Limited | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.